ConductScience.org, home

Paper24470592

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat N and 13 others. Blood, 2014. Cited by 97 papers, by iCite.

Cite this record

ConductScience Library. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Papers, record 24470592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24470592

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
PubMed
Journal
Blood
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
97
iCite
Relative citation ratio, by iCite
2.51
iCite
Revised in PubMed
2021-10-21
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bhagwat NNeha
2Koppikar PPriya
3Keller MMatthew
4Marubayashi SSachie
5Shank KKaitlyn
6Rampal RRaajit
7Qi JJun
8Kleppe MMaria
9Patel HJHardik J
10Shah SKSmit K
11Taldone TTony
12Bradner JEJames E
13Chiosis GGabriela
14Levine RLRoss L

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Genetic TherapyMajor topic
Janus Kinase 2Major topic
Molecular Targeted TherapyMajor topic
Myeloproliferative DisordersMajor topic
Amino Acid Substitution
Animals
Bone Marrow Neoplasms
Cell Transformation, Neoplastic
Combined Modality Therapy
Gene Deletion
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Transgenic
Receptors, Thrombopoietin
Treatment Outcome

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
UL1 RR024996NCRR NIH HHSUnited StatesUL1RR024996PubMed and NIHNIH RePORTER
R01 CA155226NCI NIH HHSUnited StatesR01CA155226PubMed and NIHNIH RePORTER
R01 CA169784NCI NIH HHSUnited StatesR01CA169784PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P01 CA186866NCI NIH HHSUnited StatesP01CA186866PubMed and NIHNIH RePORTER
R01 CA172546NCI NIH HHSUnited StatesR01CA172546PubMed and NIHNIH RePORTER
R01 CA151949NCI NIH HHSUnited StatesR01CA151949PubMed and NIHNIH RePORTER
1R01CA151949-01NCI NIH HHSUnited StatesR01CA151949PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in24677402Increasing therapeutic efficacy in MPN.https://conductscience.org/library/papers/24677402

Source PubMed

Download CSV of comments and corrections

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116834459MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.PLoS Med2006https://conductscience.org/library/papers/16834459PubMed
215793561A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Nature2005https://conductscience.org/library/papers/15793561PubMed
321926964Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.Leukemia2012https://conductscience.org/library/papers/21926964PubMed
420852385HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.J Clin Invest2010https://conductscience.org/library/papers/20852385PubMed
59590173Jak2 is essential for signaling through a variety of cytokine receptors.Cell1998https://conductscience.org/library/papers/9590173PubMed
622684457Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.Cancer Discov2012https://conductscience.org/library/papers/22684457PubMed
715837627Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer Cell2005https://conductscience.org/library/papers/15837627PubMed
821946277Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.Nat Chem Biol2011https://conductscience.org/library/papers/21946277PubMed
915737014Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med2005https://conductscience.org/library/papers/15737014PubMed
1020541703Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.Cancer Cell2010https://conductscience.org/library/papers/20541703PubMed
1115354294Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice.Genesis2004https://conductscience.org/library/papers/15354294PubMed
1211423618Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science2001https://conductscience.org/library/papers/11423618PubMed
1315781101Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet2005https://conductscience.org/library/papers/15781101PubMed
1422916261Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.PLoS One2012https://conductscience.org/library/papers/22916261PubMed
1522820254Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.Nature2012https://conductscience.org/library/papers/22820254PubMed
1622375971A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med2012https://conductscience.org/library/papers/22375971PubMed
1716392823Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.J Med Chem2006https://conductscience.org/library/papers/16392823PubMed
1822504184Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Nature2012https://conductscience.org/library/papers/22504184PubMed
1917267906JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.N Engl J Med2007https://conductscience.org/library/papers/17267906PubMed
2020154217Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.Blood2010https://conductscience.org/library/papers/20154217PubMed

See all 22 referencesDownload CSV of references

Cited by73

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 97 citations.

PMIDTitleJournalYearIn PapersSource
41629621JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.Leukemia2026https://conductscience.org/library/papers/41629621PubMed
41507381Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.Leukemia2026https://conductscience.org/library/papers/41507381PubMed
39104388Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms.Front Pharmacol2024https://conductscience.org/library/papers/39104388PubMed
39006945Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.Mol Ther Oncol2024https://conductscience.org/library/papers/39006945PubMed
38230747Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.Cancer Discov2024https://conductscience.org/library/papers/38230747PubMed
38177095Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.Blood Cancer J2024https://conductscience.org/library/papers/38177095PubMed
37992313Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.Clin Cancer Res2024https://conductscience.org/library/papers/37992313PubMed
37771602Recent advances in therapies for primary myelofibrosis.Fac Rev2023https://conductscience.org/library/papers/37771602PubMed
37206258Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.EJHaem2023https://conductscience.org/library/papers/37206258PubMed
36229595JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.Leukemia2022https://conductscience.org/library/papers/36229595PubMed
36044173Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.Invest New Drugs2022https://conductscience.org/library/papers/36044173PubMed
35903543JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.Front Cell Dev Biol2022https://conductscience.org/library/papers/35903543PubMed
35082276JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.Blood Cancer J2022https://conductscience.org/library/papers/35082276PubMed
34775887Novel strategies for challenging scenarios encountered in managing myelofibrosis.Leuk Lymphoma2022https://conductscience.org/library/papers/34775887PubMed
34110416Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.Blood2021https://conductscience.org/library/papers/34110416PubMed
34023895LigAdvisor: a versatile and user-friendly web-platform for drug design.Nucleic Acids Res2021https://conductscience.org/library/papers/34023895PubMed
33882481Accelerated Phase of Myeloproliferative Neoplasms.Acta Haematol2021https://conductscience.org/library/papers/33882481PubMed
33782031Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.Clin Cancer Res2021https://conductscience.org/library/papers/33782031PubMed
33472356Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.Haematologica2021https://conductscience.org/library/papers/33472356PubMed
33403355Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.Hemasphere2021https://conductscience.org/library/papers/33403355PubMed

See all 73 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HSP90AA13320PubTator's text mininghttps://conductscience.org/library/genes/3320NCBI Gene
JAK23717PubTator's text mininghttps://conductscience.org/library/genes/3717NCBI Gene
MPL4352PubTator's text mininghttps://conductscience.org/library/genes/4352NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24470592

GET https://conductscience.org/api/papers/v1/24470592/references?page=2